To estimate annual per-patient health services utilization and costs of retinitis pigmentosa (RP) in the United States. Methods: A retrospective claims analysis of patients with RP (N=2990) and a 1:1 exactly matched cohort of non-RP patients was conducted using the MarketScan Commercial and Medicare Supplemental Databases. Individuals were continuously enrolled in a commercial health plan or employer-sponsored health insurance for at least 1 year. The following annual outcomes were analyzed using nonlinear multivariate models: inpatient hospital admissions, inpatient hospital days, emergency department visits, outpatient physician visits, and prescription drug refills and inpatient and outpatient medical, pharmacy, and total health care costs. Results: Patients with RP had 0.04 more hospital admissions (PϽ.001), 0.19 more inpatient hospital days (P Ͻ .02), 0.05 more emergency department visits (PϽ.01), 2.74 more outpatient visits (PϽ.001), and 2.18 additional prescription drug fills (PϽ.